Advertisement

Topics

Amid Acquisition Drama, Celgene Resubmits MS Drug for FDA Approval

19:54 EDT 25 Mar 2019 | Xconomy

Celgene said Monday it has again sent the FDA an application for approval of ozanimod, an experimental multiple sclerosis drug it added to its pipeline in 2015 as part of its $7.2 billion acquisition of San Diego’s Receptos. Just over a year ago, the FDA refused to review Celgene’s application for ozanimod, citing a lack […]

Original Article: Amid Acquisition Drama, Celgene Resubmits MS Drug for FDA Approval

NEXT ARTICLE

More From BioPortfolio on "Amid Acquisition Drama, Celgene Resubmits MS Drug for FDA Approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...